Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

by Alberto J. Lorenzatti, Maria Laura Monsalvo, J. Antonio G. López, Huei Wang, Robert S. Rosenson
Published 2021-04-01

Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies

by Heidi T. May, Joseph B. Muhlestein, Yuhui Ma, J. Antonio G. López, Blai Coll, John Nelson
Published 2019-03-01

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies

by Michael J. Koren, Peter H. Jones, Jennifer G. Robinson, David Sullivan, Leslie Cho, Thomas Hucko, J. Antonio G. Lopez, Alex N. Fleishman, Ransi Somaratne, Erik Stroes
Published 2020-06-01

PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults

by Matthew T. Mefford, Santica M. Marcovina, Vera Bittner, Mary Cushman, Todd M. Brown, Michael E. Farkouh, Sotirios Tsimikas, Keri L. Monda, J. Antonio G. López, Paul Muntner, Robert S. Rosenson
Published 2019-11-01